866933-46-2

Basic information

• Product Name: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide
• Synonyms: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide;3-QuinolinecarboxaMide, 1,2-dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[Methyl(Methylsulfonyl)aMino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-Methylethyl)-2-oxo-;TD 5108;Velusetrag;HXLOHDZQBKCUCR-WOZUAGRISA-N
• CAS NO: 866933-46-2
• Molecular Formula: C25H36N4O5S
• Molecular Weight: 504.64214
• Mol File: 866933-46-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.34
• CAS DataBase Reference: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide(866933-46-2)
• EPA Substance Registry System: 1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide(866933-46-2)

Safety Data

• Hazardous Substances Data: 866933-46-2(Hazardous Substances Data)

Usage

General Description

The chemical "1,2-Dihydro-N-[(3-endo)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-2-oxo-3-quinolinecarboxamide" is a complex compound with various functional groups and a long molecular structure. It contains a quinoline ring and an amide group, as well as a bicyclic structure. The compound is a derivative of quinoline and has potential biological activity due to its complex structure, which includes a nitrogen-containing heterocyclic ring and an amide functional group. The compound may have potential applications in medicinal chemistry and drug development due to its unique structure and potential biological activity.

Upstream product

• 866777-83-5 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-aza-bicyclo[3.2.1]oct-3-yl}amide trifluoroacetate 
• 866777-98-2 N-methyl-N-[(S)-2-oxiran-2-ylmethyl]methanesulfonamide 
• 158577-01-6 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid 
• 174486-98-7 1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxylic acid chloride 
• 103718-15-6 2-(isopropylamino)benzaldehyde 
• 28957-72-4 N-benzylnortropinone 
• 106898-71-9 2-isopropylaminobenzyl alcohol 
• 174486-54-5 (1S,3R,5R)-3-[(3-isopropyl-2-oxo-1,2-dihydroquinoline-1-carbonyl)-amino]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 542-05-2 acetonedicarboxylic acid 
• 207405-68-3 tert-butyl 3-endo-amino-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 174486-91-0 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-aza-bicyclo[3.2.1]oct-3-yl}amide 
• 5226-51-7 2,2-dimethyl-1,4-dihydro-2H-3,1-benzoxazine 
• 185099-67-6 N-Boc-nortropinone 
• 5344-90-1 2-Aminobenzyl alcohol 

Relevant articles and documents

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation

Utilization of Theravance's multivalent approach to drug discovery towards 5-HT4 receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of a quinolone-tr

Crystalline form of a quinolinone-carboxamide compound

The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms.